This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
September 2026 results: flat quarterly profit, half-year profit down 93%
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.3 pts less than Nifty Microcap 250 and 2.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
September-quarter revenue was Rs 129.79 crore, up 10.1% year on year, while profit after tax was Rs 1.91 crore, nearly flat. After a Rs 1.67 crore loss in June, half-year revenue rose 4.5% to Rs 255.74 crore, but profit after tax fell 93.2% to Rs 0.24 crore. Quarterly margin on profit before interest, tax, depreciation and amortisation improved. Half-year operating cash flow was negative Rs 5.85 crore. The limited review found no issue.
Mixed: quarterly sales grew and profit stayed positive, but half-year profit fell sharply and operating cash flow stayed negative.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹129.8 Cr | ₹117.9 Cr | +10.1% |
| Operating profit | ₹2.13 Cr | ₹2.54 Cr | −16.0% |
| Profit after tax | ₹1.91 Cr | ₹1.90 Cr | +0.7% |
| EBITDA margin | 3.4% | 2.8% | +0.6 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.